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Background: The association between ulcerative colitis and adenocarcinoma determined
strategies for patient follow-up and early detection of dysplastic and neoplastic lesions.
Aims: To analyze the incidence of dysplasia in patients with ulcerative colitis, compar-
ing  clinical data of patients with and without dysplasia and check immunohistochemical
expression of p53 protein in dysplasias.
Materials and methods: We  analyzed biopsy samples and clinical data of 124 patients with
ulcerative colitis at Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Results: Dysplasia incidence was low (9.67%) and all cases with low-grade dysplasia. Patients
clinical data comparison with and without dysplasia did not show signiﬁcant statistical dif-
ferences with regard to the race, age at the start of the disease, age at last biopsy, duration and
anatomic extent of ulcerative colitis. Signiﬁcant difference was found between males and
females with predominance of males (58.34%) for dysplasia. Seventeenth biopsy samples of
12  patients with dysplasia, 5 (29.4%) were p53 positive.
Conclusions: From these results it is concluded that the incidence of dysplasia was low, higher
in  males and there was positivity of p53 protein in dysplasia.©  2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
 Study conducted at the Department of Pathology, Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brazil.
 Presented as a poster at the XXV Brazilian Congress of Pathology, Natal, RN, 2005.
∗ Corresponding author.
E-mail: antoniobaldinjr@ufpr.br, ksbaldin@ig.com.br (A. Baldin Júnior).
http://dx.doi.org/10.1016/j.jcol.2014.02.009
2237-9363/© 2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All rights reserved.
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Estudo  clínico-patológico  e  da  expressão  da  proteína  p53  nas  displasias
associadas  à  retocolite  ulcerativa
Palavras-chave:
Retocolite ulcerative
Displasia
Proteína p53
r  e  s  u  m  o
Racional: A associac¸ão entre retocolite ulcerativa e adenocarcinoma determinou estratégias
para seguimento dos pacientes e detecc¸ão precoce das lesões displásicas e neoplásicas.
Objetivos: Analisar a incidência de displasia nos pacientes com retocolite ulcerativa,
comparar dados clínicos dos pacientes com e sem displasia e veriﬁcar a expressão imunois-
toquímica da proteína p53 nas displasias.
Material e Métodos: Foram estudados os exames anatomopatológicos e dados clínicos de 124
pacientes com e sem displasia, portadores de retocolite ulcerativa no Hospital de Clínicas
da  Universidade Federal do Paraná.
Resultados: A incidência de displasia foi de 9,67% e todos os casos foram de displasia de
baixo grau. Na comparac¸ão dos dados clínicos dos pacientes com e sem displasia não houve
diferenc¸a  estatisticamente signiﬁcativa com relac¸ão à cor, idade no início da doenc¸a, idade
na  última biópsia, extensão da doenc¸a e tempo de evoluc¸ão da doenc¸a. Houve diferenc¸a
estatística com predomínio de pacientes do sexo masculino (58,34%) em relac¸ão ao feminino
para displasia. Dos 17 exames avaliados de 12 pacientes com displasia, em 5 exames (29,4%)
a  expressão da proteína p53 foi positiva.
Conclusões: Desses resultados conclui-se que a incidência de displasia foi baixa, maior no
sexo  masculino e houve positividade da proteína p53 nas displasias.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.
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onset of the disease (ulcerative colitis) and the time of identi-ntroduction
lcerative colitis (UC) falls within the group of chronic inﬂam-
atory bowel diseases of unknown cause. With outbreaks
f remission and exacerbation, UC has an incidence of 3–20
ew cases per year per 100,000 inhabitants.1 UC with over
 years of evolution represents an important risk factor for
he development of dysplasia and subsequent development of
denocarcinoma.2,3 The increased replacement (turnover) of
ntestinal epithelial cells damaged by chronic inﬂammation
s considered a risk factor for the development of dyspla-
ia and adenocarcinoma in patients with long progression.4
he risk of developing colorectal cancer varies from 5.5%
o 13.5%, and risk factors include the extent of disease and
he progression time.5 Monitoring and follow-up of patients
re performed by means of colonoscopies and serial biop-
ies, but these cover less than 0.05% of the colic surface.6
enetic alterations have been studied to characterize dysplas-
ic lesions and for an early detection of carcinogenesis.5 Of
ll the markers studied, the expression of p53 protein has
emonstrated signiﬁcant correlation with duration of disease,
s a risk factor of developing colorectal cancer associated with
C.7
Although the expression of p53 is a late event in colorectal
arcinogenesis, it is considered an early event in the onset of
ysplasia associated with UC.8 The onset of expression of p53,
y an abnormal protein, in the nucleus of epithelial cells of the
ntestinal mucosa occurs even without the presence of dyspla-
ia and precedes the development of dysplasia and colorectal
ancer.9Material
A retrospective study was performed since 2004 in 124
patients with clinical and endoscopic diagnosis of UC fol-
lowed at the inﬂammatory bowel diseases outpatient service,
Hospital de Clinicas, Universidade Federal do Paraná, and
who underwent pathological examination of the colonic
mucosa. This study was approved by the Research Ethics
Committee, Hospital de Clinicas, with CEP/HC 732.151/2003-
10 protocol. In the database of the Department of Pathology
of the same hospital, all patients and their respective exams
were reviewed. A clinical data survey was conducted for age,
gender, race, progression time of the disease until the time of
examination, and extent of disease. Pathological lab workup
included endoscopic biopsies and surgical specimens. The
pathological reports in which were mentioned “indeﬁnite for
dysplasia (IND)”, “presence of dysplasia” or “adenocarcinoma”
were selected.
In cases with dysplasia and in two cases of colic adeno-
carcinoma, immunohistochemical reactions for nuclear p53
protein were performed.
Method
This study included 124 patients with ulcerative colitis,
followed-up by biopsies, and the time elapsed between theﬁcation of dysplasia was registered. Patients without dysplasia
had recorded their follow-up to the last biopsy. The study vari-
ables were: race, gender, age at onset, age at last biopsy and
j). 2 0 1 4;3  4(3):136–140
Fig. 1 – Area of dysplasia. Note: Dysplastic nuclei dark
dysplasia-free time (p = 0.0242). The progression of disease in
patients with and without dysplasia showed no difference
(p = 0.8055).138  j coloproctol (rio 
site of disease. The explanatory variables were dichotomized
by testing the null hypothesis of distributions of dysplasia-
free time (time elapsed from disease progression to diagnosis
of dysplasia, or to the last biopsy) equal in both classiﬁcations
versus the alternative hypothesis of different distributions of
dysplasia-free time. The statistical test used was considered
the Cox-Mantel test. The evaluation of the progression time of
the groups with and without dysplasia was performed using
the non-parametric Mann–Whitney test. p values <0.05 were
considered statistically signiﬁcant.
The indeﬁnite cases for dysplasia and those with dysplasia
were reviewed with the use of a discriminant classiﬁcation to
characterize dysplasia as atypia or repair.10 After reviewing
the pathological examination reports, the cases were clas-
siﬁed as “with dysplasia”, “without dysplasia” or “indeﬁnite
for dysplasia”. The parafﬁn-impregnated material was cut in
4-mm thick-sections. Preparation of immunohistochemistry
slides and their deparafﬁnization and hydration with xylene
and decreasing concentrations of ethanol were performed, as
well as antigen retrieval with citrate buffer. Mouse monoclonal
antibody anti-p53 protein in previously parafﬁned material
was used. This a monoclonal antibody of immunoglobulin G2
class, that binds to both the wild-type and to the mutated
protein. The antibody was used at a dilution of 1:100. A
reaction using the streptavidin–biotin-peroxidase complex,
using colon adenocarcinoma p53-positive as positive con-
trol, was performed. A counting of brown-stained nuclei by
means of an image  analyzer (Image-Pro Plus® – The proven
solutionTM Version 4.5.1.23 for Windows 98/NT/Me/2000/XP
Copyright©1993–2002 Media Cybernetics Inc.) was performed.
Positive cells with nuclei strongly brown-stained were counted
by the program by color difference versus nuclei in blue (neg-
ative cells). Lesions with less than 10% positive cells were
negative for p53; between 1% and 25%, positive +, between
26% and 50%, positive ++, greater than 50%, positive +++.11
Results
Thirty-eight (30.65%) male and 86 (69.35%) female patients
were recruited. Nine (7.26%) were black or mestizo patients
and 115 (92.74%) were Caucasians. Clinical data (age, age at
onset of disease, disease duration, and number of biopsies)
are shown in Table 1.
Regarding the extent of disease, 78 (62.90%) patients had
only involvement of left colon and 46 (37.09%) exhibited pan-
colitis.
Of the 124 patients, in 12 (9.67%) we found 20 patholog-
ical examinations diagnosed with low-grade dysplasia (LGD)
or IND, 17 with LGD (Fig. 1) and 3 with IND. No examination
with high-grade dysplasia was found.
Two female patients with adenocarcinoma had concurrent
dysplasia. One patient developed adenocarcinoma in hepatic
colonic ﬂexure, after 8 years of disease progression, with stage
T2 N0 M0;  Astler-Coller B1; Dukes A. Another patient pre-
sented with rectal adenocarcinoma with signet ring cells areas
after 12 years of disease progression, with stage T2 N1 M0;
Coller Astler-C1-2; Dukes C.
Of the 17 tests evaluated (from 12 patients with dysplasia),
in 5 (29.4%) the result was p53-positive (Fig. 2) and in 12 (70.6%)blue-stained. HE 400×.
Source:  Department of Pathology, UFPR.
was p53-negative. An examination with positivity + (24% of
cells), 1 with positivity ++ (39% of cells) and 3 with positivity
+++ (> 50% of cells). Two cases of dysplasia were associated
with a mass (DALM), with a positivity +++. The female patient
with a rectal tumor was p53-positive +++ and the other patient
had her tumor in right colon ﬂexure was p53-negative.
In the statistical analysis with dichotomized variables,
dysplasia-free time did not correlate with race (p = 0.9467) nor
with the extent of the disease (p = 0.1551). The age before or
after 15 years at disease onset and patient age <40 years or ≥40
years at the last biopsy did not correlate with dysplasia-free
time (p = 0.8882 and p = 0.7920 respectively). In Fig. 3, it appears
that males had higher incidence of dysplasia in relation toFig. 2 – Dysplasia p53-positive. Note: Dysplastic nuclei
brown-stained brown before marking for cell count.
Immunohistochemistry for p53, 400×.
Source: Department of Pathology, UFPR.
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Table 1 – Clinical data.
Variable n Minimum Maximum Median Mean Standard
deviation
Age at last biopsy 124 10.00 81.00 39.00 39.71 13.48
Age at the beginning of the disease 124 3.00 79.00 32.50 33.90 13.56
Disease duration at last biopsy 124 1.00 36.00 5.00 6.81 5.97
Nr. of biopsies 124 1.00 10.00 3.00 3.60 2.17
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Table 2 – Frequency distribution of disease duration at
last biopsy.
Follow-up (years) Without dysplasia With dysplasia
Frequency Percentage Frequency Percentage
<5 50 44.64 4 33.33
5–9.9 35 31.25 5 41.67
10–14.9 16 14.29 3 25.00
15–19.9 7 6.25 – –
≥20 4 3.57 – –Source: The Author.
iscussion
he medical attention is focused on the monitoring of patients
ith UC, and the dysplasia found in pathological examina-
ions became the most signiﬁcant predictive factor of cancer.12
ne study found 13.1% of dysplasia in 590 patients undergoing
roctocolectomy and determined that the positive predictive
alue for colonic cancer of a preoperative ﬁnding of dysplasia
f any grade is 50%.13
Low-grade dysplasia can be detected in 17% of patients
uring follow-up with endoscopic biopsies.14 In this study,
GD was detected in 12 patients (9.67%). Higher incidence
f dysplasia in patients with concomitant adenocarcinoma is
elated; in our sample, two patients who had adenocarcinoma
lso had LGD.13
Some authors found a ﬁve -fold higher incidence of can-
er in patients with pancolitis than in patients with left side
olitis.15 Another study found 18 patients with LGD; 17 of them
ad pancolitis (94%).16 In this study, disagreeing with the ﬁnd-
ngs of the authors above mentioned, of the 12 patients with
ysplasia, seven (58.30%) had pancolitis and ﬁve (41.70%) had
eft colitis. The extent of disease did not inﬂuence the occur-
ence of dysplasia with statistical signiﬁcance (p = 0.1551).
The time of disease progression is cited as a risk factor for
olorectal cancer.15,17 In our sample there was no agreement
ith this observation (Table 2). The comparison of groups with
nd without dysplasia showed no signiﬁcant difference with
egard to time of disease progression (p = 0.8055).
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Fig. 3 – Dysplasia-free time and gender.
Source:  The author.Total 112 100.00 12 100.00
Source: The Author.
In this study there was a predominance of white patients,
which is also observed in the United States.18 In this series,
the group with dysplasia had 11 white patients and one black
patient. However, when analyzing the inﬂuence of race and
free dysplasia-free time, there was no signiﬁcant difference
(p = 0.9467).
The expression of the nuclear protein p53 has been studied
as a marker for displasia.7 Although the mutation of the p53
gene is considered to be a late event in the carcinogenesis of
sporadic colonic cancers, in the cancer associated with colitis,
the mutation appears as an earlier event.7,9 In this sample,
ﬁve exams with LGD were p53-positive (29.4%). This ﬁnding is
consistent with the literature, where LGD positivity indexes of
25–50% are found.9,19
In this study, the tests with DALM showed dense stain-
ing (+++) for p53. The presence of a DALM injury correlates in
43% of cases with a concurrent ﬁnding of adenocarcinoma.2
A strong expression of p53 is found in DALM and not in
adenoma.20
In the United States, women are more  affected by UC
than men.18 Accordingly, we  found a female predominance
in patients with ulcerative colitis (69.35%). The European epi-
demiological study was discordant from the USA study and
found higher incidence in men  in the age groups above 35
years.21 In our sample, we found more  men  in the group with
dysplasia, and the statistical analysis showed a signiﬁcant
difference (p = 0.0242). Some studies have found a higher pro-
portion of cases with dysplasia and colorectal cancer in males,
but there was no statistical assessment of the signiﬁcance of
this difference in relation to gender.22–24
ConclusionsThe incidence of dysplasia was lower than that in the liter-
ature. Patients with colorectal carcinoma had concomitant
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dysplasia. The incidence of dysplasia was signiﬁcantly higher
in males. The expression of p53 protein in dysplasias was con-
sistent with the literature.
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